Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

The Farawave NAV ablation catheter and the Faraview software are used with the Farapulse field ablation system to provide ...

Boston Scientific increased its annual profit forecast on Wednesday, fueled by strong demand for its cardiac implants, but temporarily halted a pivotal heart equipment study citing unexpected events.

Stifel analyst Rick Wise said Boston Scientific can now offer “one-stop-shopping” with a pulsed field ablation catheter and ...

Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...

Boston Scientific collected a set of FDA green lights for an update to its pulsed field ablation system for atrial ...

SGMC Health recently announced Kamil Hanna, MD, a cardiac electrophysiologist, has successfully performed the first Farapulse ...

William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...

Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...